Pharmacy Learning Network Chicago Conference - May 11-12, 2012

Regional Meeting

Live Regional Meeting

May 11-12, 2012
The Hyatt Regency O'Hare

Sponsored by North American Center for Continuing Medical Education, LLC

Register Together and Save!
Bring a Colleague for our best rates:
2 Oncology Registrations only $50
2 General Session Registrations only $75
Bring a colleague to both PLN Oncology and PLN General Session for only $110 BEST DEAL!

Super Saver Individual Rates Extended!
PLN Oncology – $40
PLN General Session – $60
PLN 2-day - $85

PLN Oncology
Based on the evolving treatment landscape and outcry from learners and faculty, NACCME has launched Pharmacy Learning Network Oncology, integrating a series of conferences and multimedia activities dedicated to educating oncology pharmacists and oncology-focused health-system pharmacists into the established Pharmacy Learning Network format. Pharmacy Learning Network Oncology conferences will focus exclusively on cancer-related topics and will consist of 4 separate 1-hour educational sessions.

PLN Oncology - May 11, 2012

8:15 am - 9:15 am	Registration and Buffet Breakfast	Exhibit Hall Open to All Attendees
9:15 am - 9:30 am	Welcome and Opening Remarks Val R. Adams, PharmD, FCCP, BCOP Associate Professor University of Kentucky
9:30 am - 10:30 am	Breast Cancer Evolving Treatment Strategies for the Spectrum of Breast Cancer Care: Implications of Biomarkers, Adjuvant Agents, and Targeted Therapy 276-000-12-012-L01-P
	Christine M. Walko, PharmD, BCOP Assistant Professor University of North Carolina School of Pharmacy	Learning Objectives Discuss the pathogenesis of breast cancers, including genetic and molecular factors that may influence testing needs and treatment selection Evaluate the role of adjuvant bisphosphonate therapy based on clinical staging and patient characteristics Outline the safety, efficacy, and mechanisms-of-action of newer and investigational targeted breast cancer therapies
10:30 am - 11:00 am	Morning Break	Exhibit Hall Open to All Attendees
11:00 am - 12:00 pm	Non-Small Cell Lung Cancer New Frontiers in the Management of Non-Small-Cell Lung Cancer: Discerning the Role and Managing Side Effects of Novel and Emerging Agents 276-000-12-011-L01-P
	Hai Tran, PharmD Associate Professor University of Texas MD Anderson Cancer Center R. Donald Harvey, PharmD, FCCP, BCPS, BCOP Assistant Professor, Hematology/Medical Oncology Winship Cancer Institute of Emory University	Learning Objectives Outline the angiogenesis process and potential role of NSCLC treatment targets Analyze the benefits and limitations of available and investigational agents for medical and radiologic NSCLC treatment Mitigate adverse effects associated with novel NSCLC pharmacotherapies Make informed medication recommendations for the management of NSCLC patients, including those experiencing treatment resistance
12:00 pm - 12:45 pm	Lunch Product Theater	Sponsored by Novartis Oncology
12:45 pm - 1:45 pm	Colorectal Cancer Optimizing Metastatic Colorectal Cancer Outcomes: Ensuring Treatment Continuity through Appropriate Drug Shortage and Supportive Care Strategies 276-000-12-010-L01-P
	Val R. Adams, PharmD, FCCP, BCOP Associate Professor University of Kentucky Marlo Blazer, PharmD, BCOP Specialty Practice Pharmacist The Ohio State University	Learning Objectives Describe the pathogenesis of colorectal cancers including genetic and molecular factors that may influence testing needs and treatment selection Employ strategies to address treatment shortages in colorectal cancer management Outline the benefits, limitations, and guideline-directed role of traditional and novel therapies for metastatic colorectal cancer Mitigate the impact of treatment side effects to ensure colorectal cancer treatment regimen continuation and improved patient outcomes
1:45 pm - 2:30 pm	Afternoon Product Theater	Sponsored by Hospira
2:30 pm - 3:30 pm	Multiple Myeloma Optimizing Multiple Myeloma Treatment and Supportive Care: Discerning the Role of Available and Investigational Pharmacotherapies 276-000-12-009-L01-P
	Christopher A. Fausel, PharmD, BCPS, BCOP Clinical Director Oncology Pharmacy Services Indiana University Simon Cancer Center David G. Frame, PharmD Assistant Professor University of Michigan College of Pharmacy	Learning Objectives Examine the characteristics and clinical and economic burden of multiple myeloma (MM) Differentiate current MM treatment standards and algorithms for first-line, refractory, and maintenance therapy Evaluate the clinical profiles of investigational therapies for MM management Implement supportive-care strategies to improve MM patient care

PLN General Session
Attended by over 3300 pharmacists since its inception in 2009, the PLN General Session has come to serve as the leading regional education platform for health-system pharmacists. Providing 6 distinct 1-hour continuing education sessions across an array of clinical areas led by expert faculty, PLN General Session provides insight into applying evidence-based guidelines and protocols to daily practice. Led by expert faculty in 6 distinct clinical areas, this year’s event will continue to provide practical data that are highly individualized to health-system pharmacists.

PLN General Session - May 12, 2012

7:00 am – 8:00 am	Registration and Buffet Breakfast	Exhibit Hall Open to All Attendees
8:00 am – 8:15 am	Welcome and Opening Remarks Randolph V. Fugit, PharmD, BCPS University of Colorado Denver *Conference Moderator and PLN Advisory Chair*
8:15 am – 9:15 am	Diabetes Improving the Continuity of Diabetes Care: Optimizing Treatment from Admission through Discharge 276-000-12-006-L01-P
	Susan Cornell, PharmD, CDE, FAPhA, FAADE Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Scott R. Drab, PharmD, CDE, BE-ADM Assistant Professor of Pharmacy and Therapeutics University of Pittsburgh School of Pharmacy	Learning Objectives Discuss the AACE and ADA statements on protocols for intensive inpatient glycemic control Compare and contrast basal-bolus versus sliding-scale insulin for managing hospitalized patients with diabetes Outline the safety and efficacy of newer and emerging diabetes pharmacotherapies, including incretin-based agents and insulin analogues Integrate pharmacy strategies to minimize medication errors and close gaps in transition of care for patients with diabetes
9:15 am – 10:15 am	Hyponatremia Hyponatremia in Hospitalized Patients: A Guide for Improving Patient Outcomes and Reducing Health-System Costs 276-000-12-003-L01-P
	Michael J. Cawley, PharmD, RRT, CPFT Associate Professor of Clinical Pharmacy University of the Sciences in Philadelphia Mark A. Munger, PharmD, FCCP, FACC Professor The University of Utah College of Pharmacy	Learning Objectives Describe the morbidity, mortality, and costs of mismanaged hyponatremia Outline the benefits and risks of current and emerging hyponatremia pharmacotherapies, including their use in patients with comorbid conditions Implement evidence-based management of hyponatremia to improve patient outcomes and reduce costs
10:15 am – 10:55 am	Morning Break	Exhibit Hall Open to All Attendees
10:55 am – 11:55 am	Infection Control Minimizing the Clinical and Cost Burden of Clostridium difficile infections 276-000-12-004-L01-P
	Elizabeth S. Dodds Ashley, PharmD, MHS, FCCP, BCPS Adjunct Associate Professor of Pharmacy Practice University of Rochester Medical Center James S. Lewis II, PharmD, FIDSA Clinical Associate Professor University of Texas College of Pharmacy	Learning Objectives Quantify the rising clinical and economic burden of C difficile infection (CDI) Overcome challenges in the diagnosis and treatment of CDI, including a changing epidemiology, hypervirulent strains, treatment failure, and recurrence rates Outline the pharmacokinetics, pharmacodynamics, and adverse-effect profile of available and emerging treatment options for CDI Implement or augment treatment protocols for CDI to reduce costs and improve patient outcomes
11:55 am – 12:45 pm	Lunch Product Theater OR Lunch with Exhibit Time	Sponsored by PharMEDium
12:45 pm – 1:15 pm	Dedicated Exhibit Hall Break	Exhibit Hall Open to All Attendees
1:15 pm – 1:25 pm	Afternoon Opening Remarks Randolph V. Fugit, PharmD, BCPS *Conference Moderator and PLN Advisory Chair*
1:25 pm – 2:25 pm	Iron Deficiency Navigating the Evolving Anemia Management Landscape: Focus on Emerging Data, Agents, and Regulatory Issues 276-000-12-007-L01-P
	Nancy A. Mason, PharmD Clinical Associate Professor of Pharmacy University of Michigan Health Systems	Learning Objectives Outline the guideline-directed administration of anemia management modalities secondary to chronic conditions in nephrology, oncology, cardiology, obstetrics, and gastroenterology Summarize efficacy, toxicity, and bioequivalence data for available intravenous iron (IVFE) formulations Discuss the clinical indications and payment structures for anemia management options Describe the clinical profiles of emerging IVFE agents
2:25 pm – 3:25 pm	Ophthalmology Ophthalmology in Focus: Empowering Pharmacists to Improve Glaucoma Outcomes and Ocular Health 276-000-12-005-L01-P
	Randall Seifert, PharmD Professor University of Minnesota College of Pharmacy Tim Cernohous, PharmD, RPh PhD Candidate, Social and Administrative Pharmacy University of Minnesota College of Pharmacy	Learning Objectives Outline the safety and efficacy of available glaucoma medications, including associated adverse events of treatment Describe the factors involved in ocular inflammation and dry eye disease, including comorbid conditions, modifiable risk factors, and appropriate pharmacotherapy Take a more active role in screening, treating, and counseling patients with glaucoma and other ocular diseases Adhere to guideline-directed and evidence-based pharmacotherapy in the treatment of ophthalmic conditions
3:25 pm – 4:10 pm	Afternoon Product Theater	Sponsored by Pfizer, Inc.
4:10 pm – 5:10 pm	Medication Errors Preparing the Health-System Pharmacist: Risk Evaluation Mitigation Strategies and the Prevention of Opiate Errors 276-000-12-008-L05-P
	Matthew Grissinger, RPh, FISMP, FASCP Director, Error Reporting Programs Institute for Safe Medication Practices	Learning Objectives Discuss methods to identify, assess, and mitigate the risks associated with dosing and administration of opiates Describe the benefits and challenges facing health-system pharmacists in implementing REMS protocols Integrate high-leverage error reduction strategies, including REMS, to reduce the risk associated with opiate use Describe the latest in FDA REMS development related to CE requirements, and impact on policy and practice

*Registration Required.

Hotel Information
PLN Chicago is being held at The Hyatt Regency O'Hare

The Hyatt Regency O’Hare is located at: 9300 Bryn Mawr Avenue, Rosemont, Illinois 60018. Tel: 847-696-1234.

Parking
Parking details will be provided in the attendee reminder email sent prior to the conference. PLN makes all efforts to reduce the cost of parking at the PLN Conference, but does not guarantee parking at the hotel.

Cancellation Policy
Please note that the cut-off date for cancellation is April 27, 2012. All cancellations must be received in writing (mailed or emailed) and postmarked by that date. Full registration will be refunded only to cancellations received in writing before the above date. Registrations are transferable at any time.

Intended Learners
This activity is designed for health-system pharmacists.

Activity Overview
The interactive educational conference will occur on May 11-12, 2012 at The Hyatt Regency O'Hare. A question-and-answer session with the faculty will follow each of the 10 sessions.

Participants will be asked to complete all conference evaluations online following the conclusion of the conference. All online evaluations will be available following the conference, and will remain active for 2 weeks following the live event at www.NACCME.com/PLN.

All individuals who participate in the conference and complete and submit the evaluation form online by May 28, 2012 may immediately print their documentation of credit.

Note: Participants are eligible to receive up to 10 contact hours of continuing education credit. Participants are only eligible for credit for those sessions attended in full.

Accreditation
In support of improving patient care, North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CPE
Each of these activities is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UAN 276-000-12-003-L01-P, 276-000-12-004-L01-P, 276-000-12-005-L01-P, 276-000-12-006-L01-P, 276-000-12-007-L01-P, 276-000-12-008-L05-P, 276-000-12-009-L01-P, 276-000-12-010-L01-P, 276-000-12-011-L01-P, 276-000-12-012-L01-P).

These educational activities are knowledge-based activites.

Independent clinical reviewers will be disclosed in the final program materials.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Assistant Director, Accreditation Services, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535. The Assistant Director, Accreditation Services will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation Services, NACCME, may be made for a second level of review.

ADA Statement
North American Center for Continuing Medical Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

Hardware/Software Requirements
The evaluation is accessible after the activity via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Planning Committee
The planning committee comprises Val R. Adams, PharmD, FCCP, BCOP, George Bailie, PharmD, Marlo Blazer, PharmD, BCOP, Michael J. Cawley, PharmD, RRT, CPFT, Timothy Cernohous, PharmD, Susan Cornell, PharmD, CDE, FAPhA, FAADE, Elizabeth S. Dodds Ashley, PharmD, MHS, FCCP, BCPS, Scott R. Drab, PharmD, CDE, BE-ADM, Christopher A. Fausel, PharmD, BCPS, BCOP, David G. Frame, PharmD, Randolph V. Fugit, PharmD, BCPS, Matthew Grissinger, RPh, FISMP, FASCP, R. Donald Harvey, PharmD, FCCP, BCPS, BCOP, Marc LaPointe, PharmD, James S. Lewis II, PharmD, FIDSA, Conan MacDougall, PharmD, Nancy Mason, PharmD, Patrick McDonnell, PharmD, Mark A. Munger, PharmD, FCCP, FACC, Randall Seifert, PharmD, Sachin Shah, PharmD, Hai Tran, PharmD, Curtis Triplitt, PharmD, Christine M. Walko, PharmD, BCOP; and Kristin Ciszeski, Mary Johnson, Mike Kearney, Rich Keenan, Nick Lombardi, Randy Robbin, and John Savage, NACCME.

Financial Disclosure and Conflicts of Interest
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are indentified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations

Financial disclosures and conflicts of interest, and any off-label/unapproved uses of drugs and/or devices will be disclosed in the final activity materials.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2012 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

Grant Support
Supported in part by educational grants from American Regent, Celgene Corporation, Millennium Pharmaceuticals, Inc, and Otsuka Pharmaceuticals Co, Ltd.

Representatives of the granting organization may not register on behalf of participants.